E ach year at the end of June, Thomson Reuters releases journal impact factors (IFs), a measure reflecting the average number of citations to articles published in each journal over the two previous years and generally accepted as a proxy for the relative importance of a journal among others serving a particular field. As discussed below, one can debate the wisdom of reliance on this particular citation metric, although Molecular Therapy has indeed benefited from many consecutive years of increases in the IF. Coupled with our commitment to rapid and fair review, the increases in our IF have been key to our being able to attract high-quality research papers in cell and gene therapy.